Protagonist Therapeutics, Inc
Company Stats
- Market Cap
- $9.1B
- as of Sep 30, 2026
- Shares Outstanding
- 64.7M
- Free Float
- 94.6%
Income Statement
- Revenue
- $46.0M
- Operating Income
- -$158.1M
- Net Income
- -$130.1M
- EBITDA
- -$156.8M
- Revenue Growth, 3Y
- 20.1%
- FCF Margin, 3Y Avg
- 15.3%
- FCF Margin, Worst Year
- -118.1%
Cash Flow
- Free Cash Flow
- $56.1M
- FCF Yield
- 0.6%
- Owner FCF Yield
- 0.1%
Balance Sheet
- Cash & Equivalents
- $128.4M
Returns & Capital
- SBC, 3Y Avg
- $37.6M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $46.0M | $56.1M | 121.9% |
| FY2024 | $434.4M | $182.8M | 42.1% |
| FY2023 | $60.0M | -$70.8M | -118.1% |
| FY2022 | $26.6M | -$108.9M | -409.8% |
| FY2021 | $27.4M | -$109.0M | -398.3% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 28, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Earnings
Other Coverage
October 14, 2026
Theme Survey
GLP-1 companies reshape access and detail treatment dropouts
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
August 14, 2026
Industry Earnings Roundup
Healthcare Earnings: Demand Surges, Costs Bite Back
August 4, 2026
Theme Survey
GLP-1 Shift: Branded Access and Oral Formulations Gain Ground
GLP-1 companies reshape access and detail treatment dropouts
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
August 14, 2026
Industry Earnings Roundup
Healthcare Earnings: Demand Surges, Costs Bite Back
August 4, 2026
Theme Survey
GLP-1 Shift: Branded Access and Oral Formulations Gain Ground